High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

Por Qiao, G-B, Wu, Y-L, Yang, X-N, Zhong, W-Z, Xie, D, Guan, X-Y, Fischer, D, Kolberg, H-C, Kruger, S, Stuerzbecher, H-W
Publicado em 2005

Serum C-reactive protein predicts poor prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy

Por Zeng, Y.C., Wu, R., Xiao, Y.P., Chi, F., Xue, M., Zhang, Z.Y., Xing, R., Zhong, W.Z., Wang, S.L., Tian, X., Chen, W., Chen, J.J., Wu, L.N.
Publicado no Curr Oncol (2015)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

Por Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C, Jiang, B Y, Bai, X Y, Zhong, W Z, Yang, X N, Wu, Y L
Publicado no Br J Cancer (2017)